Evidence behind quality of care measures for venous thromboembolism and atrial fibrillation

Journal of Thrombosis and Thrombolysis

Volumn 37, Issue 2, 2014, Pages 87-96

  Eymin, G ^a,b   Jaffer, A K ^a,c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c NONE   (United States)

Author keywords

Atrial fibrillation; Dabigatran; Rivaroxaban; Stroke; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; APIXABAN; DABIGATRAN ETEXILATE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; COMPRESSION STOCKING; DEEP VEIN THROMBOSIS; DRUG CONTRAINDICATION; EMBOLISM; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; LEG THROMBOSIS; LOW DRUG DOSE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK FACTOR; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM; FEMALE; MALE; ORAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; QUALITY OF HEALTH CARE; VENOUS THROMBOEMBOLISM;

EID: 84894652130     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0874-3     Document Type: Article

References (89)

1. Heit JA, Cohen AT, Anderson FA (2005) Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood 106:910
2. Roger VL, Go AS, Lloyd-Jones DM et al (2012) Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125:e2-e220
3. Fuster V, Rydén LE, Cannom DS et al (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 57:e101-e198
4. Guyatt GH, Akl EA, Crowther M et al (2012) Executive summary: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:7S-47S
5. Joint Commission on Accreditation of Healthcare Organizations (2008) Venous thromboembolism prophylaxis. Available at: www.jointcommission.org/ venous-thromboembolism. Accessed 8 Aug 2012
6. Raskob GE, Silverstein R, Bratzler DW et al (2010) Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med 38(4 Suppl):S502-S509
7. Cohen AT, Tapson VF, Bergmann JF et al (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371:387-394
8. American Public Health Association (2010) Deep-vein thrombosis: advancing awareness to protect patient lives. Public Health Leadership Conference on Deep-Vein Thrombosis, Washington, 26 Feb 2003. At: www.apha.org/NR/rdonlyres/ A209F84A-7C0E-4761-9ECF-61D22E1E11F7/0/DVT-White-Paper.pdf. Accessed 11 Aug 2012
9. Bratzler DW (2010) Development of national performance measures on the prevention and treatment of venous thromboembolism. J Thromb Thrombolysis 29(2):148-154
10. Joint Commission (2011) Venous thromboembolism. Available at: http://www.jointcommission.org/venous-thromboembolism/. Accessed 10 Sep 2012
11. Merli G (2010) Improving venous thromboembolism performance: a comprehensive guide for physicians and hospitalists. Hosp Pract (Minneap) 38:7-16
12. Agency for Healthcare Research and Quality (2012) National Quality Measures Clearinghouse. Measure summary NQMC-6105 (STK-1), 6107 (STK-3). Available at: www.qualitymeasures.ahrq.gov/search/search.aspx?term= vte+prophylaxis. Accessed Aug 8, 2012
13. Wolf PA, Mitchell JB, Baker CS et al (1998) Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 158:229-234
14. Goldstein LB, Adams R, Alberts MJ et al (2006) Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 37:1583-1633
15. George MG, Tong X (2011) Use of a registry to improve acute stroke care-seven states, 2005-2009. MMWR 2011;201-205, 206-210. Cited in JAMA 305:1649-1653
16. Griffin FA (2007) Reducing surgical complications. Jt Comm J Qual Patient Saf 33:660-665
17. Commission Joint (2009) Approved: more options for hospital core measures. Jt Comm Perspect 29:4-6
18. Cohn SL, Adekile A, Mahabir V (2006) Improved use of thromboprophylaxis for deep vein thrombosis following an educational intervention. J Hosp Med 1:331-338
19. Bullock-Palmer RP, Weiss S, Hyman C (2008) Innovative approaches to increase deep vein thrombosis prophylaxis rate resulting in a decrease in hospital-acquired deep vein thrombosis at a tertiary-care teaching hospital. J Hosp Med 3:148-155
20. Daniel D, Maund C, Butler K (2010) Community hospital participation in a pilot project for venous thromboembolism quality measures: learning, collaboration, and early improvement. Jt Comm J Qual Patient Saf 36:301-309
21. Joint Commission (2012) Accountability measures. Available at: www.jointcommission.org/daily-update/joint-commission-daily-update.aspx. Accessed 10 Sep 2012
22. Tapson VF, Decousus H, Pini M et al (2007) Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 132:936-945
23. Joint Commission (2012) Specifications manual for national inpatient quality measures release manual. Available at: www.jointcommission.org/ specifications-manual-for-national-hospital-inpatient-quality-measures.aspx. Accessed 10 Sep 2012
24. Qaseem A, Chou R, Humphrey LL et al (2011) Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 155:625-632
25. Agency for Healthcare Research and Quality (2012).National Quality Measures Clearinghouse. VTE prophylaxis. Available at: www.qualitymeasures.ahrq. gov/search/search.aspx?term=vte+prophylaxis. Accessed 10 September 2012
26. Heit JA (2003) The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolism. Chest 124(suppl):40S-48S
27. Michota FA (2004) Venous thromboembolism prophylaxis in medical patients. Curr Opin Cardiol 19:570-574
28. Centers for Disease Control and Prevention (CDC) (2011) Use of a registry to improve acute stroke care-seven states, 2005-2009. MMWR Morb Mortal Wkly Rep 60(7):206-210
29. Schwamm LH, Fonarow GC, Reeves MJ et al (2009) Get with the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation 119(1):107-115
30. Anderson FA Jr, Wheeler HB (1992) Physician practices in the management of venous thromboembolism: a community-wide survey. J Vasc Surg 16:707-714
31. Anderson FA Jr, Spencer FA (2003) Risk factors for venous thromboembolism. Circulation 107(23 Suppl 1):I9-I16
32. Cade JF (1982) High risk of the critically ill for venous thromboembolism. Crit Care Med 10:448-450
33. Geerts W, Selby R (2003) Prevention of venous thromboembolism in the ICU. Chest 124:357S-363S
34. Attia J, Ray JG, Cook DJ et al (2001) Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 161:1268-1279
35. Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest 133:381S-453S
36. ® (warfarin sodium) prescribing information. Bristol-Myers Squibb Company, Princeton
37. Brandjes DP, Heijboer H, Buller HR et al (1992) Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 327:1485-1489
38. Chan YC, Valenti D, Mansfield AO et al (2000) Warfarin induced skin necrosis. Br J Surg 87:266-272
39. Hull RD, Raskob GE, Hirsh J et al (1986) Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 315:1109-1114
40. Raschke RA, Reilly BM, Guidry JR et al (1993) The weight-based heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med 119:874-881
41. Warkentin TE (2004) Heparin-induced thrombocytopenia: diagnosis and management. Circulation 110:e454-e458
42. Beyth RJ, Quinn L, Landefeld CS (2000) A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized, controlled trial. Ann Intern Med 133:687-695
43. Arnold DM, Kahn SR, Shrier I (2001) Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest 120:1964-1971
44. Heit JA, O'Fallon WM, Petterson TM et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162:1245-1248
45. Spyropoulos AC, Anderson FA Jr, Fitzgerald G et al (2011) Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 140:706-714
46. Heit JA, Silverstein MD, Mohr DN et al (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160:809-815
47. Agency for Healthcare Research and Quality (2010) National Quality Measures Clearinghouse. Measure Summary NQMC-6094 (SCIP VTE-1). Available at: www.qualitymeasures.ahrq.gov. Accessed 8 Aug 2012
48. Agency for Healthcare Research and Quality (2010). National Quality Measures Clearinghouse. Measure Summary NQMC-6095 (SCIP VTE-2).Available at: www.qualitymeasures.ahrq.gov. Accessed 8 Aug 2012
49. Estes NA III, Halperin JL, Calkins H et al (2008) ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for atrial fibrillation): developed in collaboration with the Heart Rhythm Society. Circulation 117:1101-1120
50. Wann LS, Curtis AB, Ellenbogen KA, American College of Cardiology Foundation/American Heart Association Task Force et al (2011) 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123:1144-1150
51. ® (dabigatran etexilate) product information. Boehringer-Ingelheim Pharmaceuticals, Inc, Ridgefield
52. ® (rivaroxaban) product information. Janssen Pharmaceuticals, Inc, Titusville
53. McCarthy ST, Turner J (1986) Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age Ageing 15:84-88
54. International Stroke Trial Collaborative Group. International Stroke Trial (IST) (1997) A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349:1569-1581
55. Coull BM, Williams LS, Goldstein LB et al (2002) Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke 33:1934-1942
56. Duncan PW, Zorowitz R, Bates B et al (2005) Management of Adult Stroke Rehabilitation Care: a clinical practice guideline. Stroke 36:e100-e143
57. Hart RG, Pearce LA, McBride R et al (1999) Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) investigators. Stroke 30:1223-1229
58. No authors listed (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449-1457
59. Gage BF, van Walraven C, Pearce L et al (2004) Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110:2287-2292
60. Hart RG, Benavente O, McBride R et al (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131:492-501
61. No authors listed (1994) Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343:687-691
62. Hylek EM, Skates SJ, Sheehan MA et al (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335:540-546
63. Kopecky SL, Gersh BJ, McGoon MD et al (1987) The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med 317:669-674
64. Van Staa TP, Setakis E, Di Tanna GL et al (2011) A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 9(1):39-48
65. Goldhaber SZ (2004) Prevention of deep vein thrombosis and pulmonary embolism. Circulation 110:445-447
66. Gage BF, Fihn SD, White RH (2000) Management and dosing of warfarin therapy. Am J Med 109:481-488
67. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151
68. Connolly SJ, Ezekowitz MD, Yusuf S et al (2010) Newly identified events in the RE-LY trial. N Engl J Med 363:1875-1876
69. Tran A, Cheng-Lai A (2011) Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin. Cardiol Rev 19:154-161
70. Eriksson BI, Dahl OE, Rosencher N et al (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5:2178-2185
71. Eriksson BI, Dahl OE, Rosencher N et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949-956
72. Ginsberg JS, Davidson BL, Comp PC et al (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24:1-9
73. Cao YB (2010) Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 66:1099-1108
74. Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883-891
75. Lassen MR, Raskob GE, Gallus A et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375:807-815
76. Lassen MR, Gallus A, Raskob GE et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363:2487-2498
77. Budnitz DS, Lovegrove MC, Shehab N et al (2011) Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 365(21):2002-2012
78. Lassen MR, Raskob GE, Gallus A et al (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361:594-604
79. Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981-992
80. Connolly SJ, Eikelboom J, Joyner C et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806-817
81. National Quality Forum (2003) Safe practices for better healthcare: a consensus report. Available at: www.qualityforum.org. Accessed 8 Aug 2012
82. Centers for Medicare & Medicaid Services. CMS improves patient safety for Medicare and Medicaid by addressing never events. Available at: http://www.cms.gov. Accessed 8 Aug 2012
83. Centers for Medicare & Medicaid Services (2011) Medicare program; hospital inpatient value-based purchasing program. Final rule Fed Regist 76:26490-26547
84. US Department of Health & Human Services (2011) Administration implements new health reform provision to improve care quality, lower costs. Available at: www.hhs.gov. Accessed 8 Aug 2012
85. Maynard G, Stein J (2010) Designing and implementing effective venous thromboembolism prevention protocols: lessons from collaborative efforts. J Thromb Thrombolysis 29:159-166
86. Stevens SM, Douketis JD (2010) Deep vein thrombosis prophylaxis in hospitalized medical patients: current recommendations, general rates of implementation, and initiatives for improvement. Clin Chest Med 31:675-689
87. Agency for Healthcare Research and Quality (2008) Preventing hospital-acquired venous thromboembolism: a guide for effective quality improvement. Available at: http://www.ahrq.gov/qual/vtguide/. Accessed 12 Sep 2012
88. Maynard G (2010) Optimizing prevention of hospital-acquired venous thromboembolism (VTE): prospective validation of a VTE risk assessment model. J Hosp Med 5:10-18
89. McKean S, Stein J, Maynard G et al (2006) Curriculum development: the venous thromboembolism quality improvement resource room. J Hosp Med 1:124-132